德诺苏马布对功能和2型糖尿病患者患有骨质疏松症的死亡率的影响
Yu-Chuan Chang1, Jian-Chih Chen2,3, Sung-Yen Lin4,5,6,7
1School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
The Kaohsiung journal of medical sciences
|October 10, 2025
概括
在患有2型糖尿病和骨质疏松症的患者中,高度坚持denosumab治疗与较低的死亡风险有关. 在这项研究中,坚持水平并没有显著影响功能.
科学领域:
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學.
- 老年学是一门学科.
背景情况:
- 2型糖尿病 (T2DM) 会增加骨质疏松症和骨折的风险.
- 德诺苏马布为T2DM患者提供替代性骨质疏松症治疗,独立于功能.
- 调查denozumab对T2DM死亡率和功能的影响至关重要.
研究的目的:
- 检查在患有骨质疏松症的T2DM患者中,代诺苏马布粘附性,功能和全因死亡率之间的关联.
- 为了评估是否高的denosumab坚持影响功能或死亡率.
主要方法:
- 对新使用德诺苏马布 (2010-2017年) 电子病历的回顾性分析.
- 在两年内将患者分为高坚持 (3-4剂) 和低坚持 (1-2剂) 的两类.
- 使用卡普兰-梅尔曲线和考克斯回归计算了1年平均估计的膜过率 (eGFR),并使用卡普兰-梅尔曲线和考克斯回归分析了全因死亡率.
主要成果:
- 高坚持度 (n=286) 和低坚持度 (n=250) 组显示出相似的功能,两者都有轻微的EGFR下降.
- 高坚持性组显示出明显较低的全因死亡率 (调整HR:0.52;95%CI:0.29-0.92).
结论:
- 较高的德诺苏马布坚持与T2DM骨质疏松症患者全因死亡率的降低有关.
- 维持定期的德诺苏马布治疗可能有利于这种高风险人群,而不会对脏产生不良影响.
- 需要进一步的前性研究来确认因果关系并探索潜在的机制.
相关概念视频
01:29Bone Disorders
5.1K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
5.1K
01:11Renal Failure: Dose Adjustments
437
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
437
01:40Bone Remodeling
40.2K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
40.2K
01:21Drug Dosing: Obese Patients
222
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
222
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
208
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
208
01:24Chronic Kidney Disease II: Clinical Manifestations
552
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
552